Premier Alternatives

RejuvenAir

Lexington, MA · Founded 1993 · Privately Held (backing)

Developer of an interventional device designed to offer the therapy of chronic obstructive pulmonary disease with chronic bronchitis using metered cryospray. RejuvenAir is based in Lexington, MA and was founded in 1993. Its last known valuation is $156 million. It has raised $191 million.

Last price · $/share
—
Implied valuation
$156.0M
Total raised
$191.4M
Last round
—

RejuvenAir key facts

  • Developer of an interventional device designed to offer the therapy of chronic obstructive pulmonary disease with chronic bronchitis using metered cryospray.
  • RejuvenAir’s last known valuation is $156.0M.
  • It has raised $191.4M; the latest was Later Stage VC ($59.7M) in Sep 2024.
  • Notable investors include Innovate UK, TEDCO, SV Health Investors, Ascension Ventures, Rose Park Advisors — 12 tracked in total.
  • Status: Privately Held (backing).
Free account
More of RejuvenAir with a free account
  • ·The complete investor list: 12 names
  • ·Watch RejuvenAir: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

RejuvenAir funding rounds

No rounds on record

No funding rounds for RejuvenAir are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

RejuvenAir valuation

RejuvenAir's last known valuation is $156 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

RejuvenAir investors

12 investors are on record for RejuvenAir, including Innovate UK, TEDCO, SV Health Investors and Ascension Ventures. By type, the record holds 3 venture capital firms, 1 asset manager and 1 fund of funds.

About RejuvenAir

Developer of an interventional device designed to offer the therapy of chronic obstructive pulmonary disease with chronic bronchitis using metered cryospray. The company's device incorporates software-driven dosimetry and specialty catheters, enabling the medical industry to facilitate precise delivery of cryogenic spray to freeze and destroy damaged airway cells, promoting healing and reducing symptoms such as mucus production, cough, and inflammation.

Sector
Healthcare
HQ
Lexington, MA, United States
Founded
1993
Employees
31
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$156.0M

RejuvenAir’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.